School of Pharmacy, Kanazawa University.
Biol Pharm Bull. 2021;44(2):219-224. doi: 10.1248/bpb.b20-00684.
Baculovirus vectors (BVs) are safely able to transduce foreign genes and express them in mammalian cells. However, the transduction activity of BVs is strongly reduced by the attack of serum complement, which is one of the major obstacles in the use of BVs for in vivo gene transfer. One strategy to overcome this problem is the display of complement regulatory proteins (CRPs) on BV virions. We previously developed CD46-decay accelerating factor (DAF)-CD59 triple fusion type BV showing potent complement resistance. We also developed BVs expressing Plasmodium circumsporozoite protein (CSP) to enhance transduction efficacy in hepatic cells. In this study, we investigated the combination of CSP and CRPs in a BV system to evaluate transduction efficacy along with complement resistance. To accomplish the combination of CSP and CRPs, we generated insect Sf9 cells stably expressing CRPs, to which CSP type BV was infected. The BVs collected from these infected cells were confirmed to possess both CSP and CRPs in virions. We demonstrated that CSP-CD46-DAF-CD59 type BV, containing both CSP and CD46-DAF-CD59, showed a significant increase in transduction efficacy in human hepatoma HepG2 cells under intact serum exposure compared with control type BV or CSP type BV, retaining both advantages of CSP and CD46-DAF-CD59. Collectively, these results demonstrated that the utilization of stably expressing Sf9 cells to introduce the protein products of interest, e.g., CRPs into BVs, would be useful strategy to generate BVs with novel functions such as resistance against serum complement attack.
杆状病毒载体 (BVs) 能够安全地转导外源基因并在哺乳动物细胞中表达它们。然而,BVs 的转导活性会被血清补体强烈攻击,这是在体内基因转移中使用 BVs 的主要障碍之一。克服这个问题的一种策略是在 BV 病毒粒子上展示补体调节蛋白 (CRPs)。我们之前开发了 CD46-衰变加速因子 (DAF)-CD59 三重融合型 BV,表现出强大的补体抗性。我们还开发了表达疟原虫环子孢子蛋白 (CSP) 的 BVs 以增强肝细胞中的转导效力。在这项研究中,我们研究了 CSP 和 CRPs 在 BV 系统中的组合,以评估转导效力和补体抗性。为了实现 CSP 和 CRPs 的组合,我们生成了稳定表达 CRPs 的昆虫 Sf9 细胞,将 CSP 型 BV 感染这些细胞。从这些感染细胞中收集的 BVs 被证实具有病毒粒子中的 CSP 和 CRPs。我们证明,与对照型 BV 或 CSP 型 BV 相比,含有 CSP 和 CD46-DAF-CD59 的 CSP-CD46-DAF-CD59 型 BV 在完整血清暴露下在人肝癌 HepG2 细胞中的转导效力显著增加,保留了 CSP 和 CD46-DAF-CD59 的双重优势。总之,这些结果表明,利用稳定表达 Sf9 细胞将感兴趣的蛋白产物(例如 CRPs)引入 BVs 是一种有用的策略,可以生成具有抵抗血清补体攻击等新功能的 BVs。